复星医药：控股子公司斯鲁利单抗海外许可协议有新进展

Group 1 - The core point of the article is that Fosun Pharma's subsidiary, Fuhong Hanlin, has made progress in overseas licensing for its drug, Sru Li Anti-Injectable Solution [1] Group 2 - On February 24, Fuhong Hanlin signed a revised and partially terminated agreement with KGBio, ending the exclusive licensing agreement for regions outside Indonesia, with potential milestone payments of up to $33.75 million to be paid based on transfer progress [1] - Fuhong Hanlin also signed a modification to the 2024 licensing agreement with Abbott, expanding the licensing area, with Abbott potentially paying up to $46 million in regulatory milestone payments and up to $80 million in sales milestone payments [1] - The recent developments aim to expand the overseas market, but there is uncertainty regarding the collaboration with Abbott and the receipt of related payments [1]